We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Utragenyx Shares Soar Above 60% YTD on Pipeline Developments
Read MoreHide Full Article
Share price of Ultragenyx Pharma (RARE - Free Report) has surged 66.9% year to date compared with the industry’s growth of 8.4%. A few factors have led to the price increase.
The company is also looking to expand the label of Crysvita, an antibody targeting fibroblast growth factor 23 (FGF23), which was developed for the treatment of tumor-induced osteomalacia (TIO). In January 2020, the company submitted the supplemental Biologics License Application (sBLA) to the FDA after completing a pre-sBLA meeting with the FDA authorities and signing an agreement on the filing package. Subsequently, the FDA accepted the sBLA under priority review in February 2020, with a decision expected on Jun 18.
Crysvita is approved in the United States for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients. The drug’s performance has been strong. The drug received European conditional marketing authorization, in February 2018, for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older, and adolescents with growing skeletons.
An important pipeline candidate is UX007, developed for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). A new drug application seeking approval of UX007 for LC-FAOD is under standard review with the FDA, with a decision expected on Jul 31.
During the first-quarter 2020 earnings call, management confirmed that the FDA reviews of Crysvita for TIO and UX007 for LC-FAOD are on track with decisions pending on the scheduled dates.
The company also has some gene therapy candidates in its pipeline. These include DTX301, which is an adeno-associated virus 8 (AAV8) being evaluated for the treatment of patients with Ornithine transcarbamylase (OTC) deficiency. In January, Ultragenyx reported positive top-line results from the safety and efficacy data of Cohort 3 and longer-term data of Cohort 2. In May, the company announced positive longer-term safety and efficacy data from the first three cohorts of the ongoing phase I/II study on DTX301. The company is initiating a fourth cohort (n=3) using prophylactic steroids at the same dose as Cohort 3. Data from the prophylactic steroid cohort are expected in the second half of 2020.
DTX401 is also an AAV8 gene-therapy candidate, currently being evaluated for the treatment of patients with glycogen storage disease type Ia, (GSDIa). In May, Ultragenyx announced positive initial data from the confirmatory third cohort and longer-term data from the first two cohorts of the ongoing phase I/II study of DTX401 for GSDIa. Following the release of the confirmatory cohort report, a phase III study could be initiated in the second half of 2020. The FDA also granted DTX401a Fast Track status for the treatment of GSDIa.
In May, the FDA granted Fast Track designation to its investigational antisense oligonucleotide, GTX-102, for the treatment of Angelman syndrome (AS). The candidate is currently being evaluated in a phase I/II study for the treatment of AS.
Akcea’s loss per share estimates have narrowed from $2.07 to $1.37 for 2020 and from $2.46 to $1.85 for 2021 in the past 60 days.
Axcella’s loss per share estimates have narrowed from $1.14 to 79 cents for 2020 and from $3.30 to $3.03 for 2021 in the past 60 days.
Aytu’s loss per share estimates have narrowed from $1.26 to 12 cents for 2020 in the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Utragenyx Shares Soar Above 60% YTD on Pipeline Developments
Share price of Ultragenyx Pharma (RARE - Free Report) has surged 66.9% year to date compared with the industry’s growth of 8.4%. A few factors have led to the price increase.
The company is also looking to expand the label of Crysvita, an antibody targeting fibroblast growth factor 23 (FGF23), which was developed for the treatment of tumor-induced osteomalacia (TIO). In January 2020, the company submitted the supplemental Biologics License Application (sBLA) to the FDA after completing a pre-sBLA meeting with the FDA authorities and signing an agreement on the filing package. Subsequently, the FDA accepted the sBLA under priority review in February 2020, with a decision expected on Jun 18.
Crysvita is approved in the United States for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients. The drug’s performance has been strong. The drug received European conditional marketing authorization, in February 2018, for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older, and adolescents with growing skeletons.
An important pipeline candidate is UX007, developed for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). A new drug application seeking approval of UX007 for LC-FAOD is under standard review with the FDA, with a decision expected on Jul 31.
During the first-quarter 2020 earnings call, management confirmed that the FDA reviews of Crysvita for TIO and UX007 for LC-FAOD are on track with decisions pending on the scheduled dates.
The company also has some gene therapy candidates in its pipeline. These include DTX301, which is an adeno-associated virus 8 (AAV8) being evaluated for the treatment of patients with Ornithine transcarbamylase (OTC) deficiency. In January, Ultragenyx reported positive top-line results from the safety and efficacy data of Cohort 3 and longer-term data of Cohort 2. In May, the company announced positive longer-term safety and efficacy data from the first three cohorts of the ongoing phase I/II study on DTX301. The company is initiating a fourth cohort (n=3) using prophylactic steroids at the same dose as Cohort 3. Data from the prophylactic steroid cohort are expected in the second half of 2020.
DTX401 is also an AAV8 gene-therapy candidate, currently being evaluated for the treatment of patients with glycogen storage disease type Ia, (GSDIa). In May, Ultragenyx announced positive initial data from the confirmatory third cohort and longer-term data from the first two cohorts of the ongoing phase I/II study of DTX401 for GSDIa. Following the release of the confirmatory cohort report, a phase III study could be initiated in the second half of 2020. The FDA also granted DTX401a Fast Track status for the treatment of GSDIa.
In May, the FDA granted Fast Track designation to its investigational antisense oligonucleotide, GTX-102, for the treatment of Angelman syndrome (AS). The candidate is currently being evaluated in a phase I/II study for the treatment of AS.
Ultragenyx Pharmaceutical Inc. Price
Ultragenyx Pharmaceutical Inc. price | Ultragenyx Pharmaceutical Inc. Quote
Zacks Rank & Stocks to Consider
Ultragenyx currently is a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the biotech sector are Akcea Thrapeuticss Inc. , Axcella Health Inc. and Aytu BioScience Inc. (AYTU - Free Report) , all carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Akcea’s loss per share estimates have narrowed from $2.07 to $1.37 for 2020 and from $2.46 to $1.85 for 2021 in the past 60 days.
Axcella’s loss per share estimates have narrowed from $1.14 to 79 cents for 2020 and from $3.30 to $3.03 for 2021 in the past 60 days.
Aytu’s loss per share estimates have narrowed from $1.26 to 12 cents for 2020 in the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>